SDMH.F Stock Overview
Engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Sartorius Stedim Biotech S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €200.89 |
| 52 Week High | €299.86 |
| 52 Week Low | €158.00 |
| Beta | 0.67 |
| 11 Month Change | 1.33% |
| 3 Month Change | 1.54% |
| 1 Year Change | 0.57% |
| 33 Year Change | -63.86% |
| 5 Year Change | 38.18% |
| Change since IPO | 399.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| SDMH.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 3.8% | 5.1% |
| 1Y | 0.6% | 21.2% | 37.7% |
Return vs Industry: SDMH.F underperformed the US Life Sciences industry which returned 21.2% over the past year.
Return vs Market: SDMH.F underperformed the US Market which returned 37.7% over the past year.
Price Volatility
| SDMH.F volatility | |
|---|---|
| SDMH.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SDMH.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SDMH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 10,082 | Rene Faber | www.sartorius.com |
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products.
Sartorius Stedim Biotech S.A. Fundamentals Summary
| SDMH.F fundamental statistics | |
|---|---|
| Market cap | US$19.37b |
| Earnings (TTM) | US$173.40m |
| Revenue (TTM) | US$2.95b |
111.7x
P/E Ratio6.6x
P/S RatioIs SDMH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SDMH.F income statement (TTM) | |
|---|---|
| Revenue | €2.74b |
| Cost of Revenue | €1.55b |
| Gross Profit | €1.19b |
| Other Expenses | €1.02b |
| Earnings | €160.60m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.65 |
| Gross Margin | 43.33% |
| Net Profit Margin | 5.87% |
| Debt/Equity Ratio | 68.4% |
How did SDMH.F perform over the long term?
See historical performance and comparison